Trial · NCT02145715
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
NCT02145715, Phase 1, Phase 2, Unknown, Prof Jamie Cavenagh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma. Trials, record NCT02145715. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02145715
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
- NCT number
- NCT02145715
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 54 participants, estimated
- Lead sponsor
- Prof Jamie Cavenagh
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Thalidomide, Dexamethasone, Panobinostat
- First posted
- 2014-05-23
- Last updated
- 2015-06-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose limiting toxicities (DLTs) | From cycle 1 day 1 up to the administration of cycle 2 day 1 (up to 22 days) | The number of participants experiencing DLTs within the first cycle of VTD-pano will be presented, with descriptive summaries of the specific DLTs observed. Summaries will be presented for each dose level. |
| Primary | Proportion o f participants achieving at least partial response | within 16 cycles of therapy (an expected average of 48 weeks) | The proportion of participants achieving at least a partial response within 16 cycles of VTD-pano will be presented, with corresponding 80% and 95% confidence intervals |
| Secondary | Safety and toxicity | Throughout the trial, expected to be 3 years | The proportion of participants experiencing DLTs and other toxicities, overall and by cycle as graded by CTCAE V4.0. |
| Secondary | Proportion of patients with each maximum response category | within 16 cycles of therapy (an expected average of 48 weeks) | The number and proportion of participants in each response category within 16 cycles of VTD-pano will be presented with corresponding 95% confidence intervals. |
| Secondary | Time to maximum response to therapy | from registration until the participant achieves any of the categories CR, VGPR, PR, MR or SD as their maximum response (up to 100 weeks - 48 weeks of treatment plus 52 weeks maintenance) | Time to maximum response is defined as the time from registration until the patient achieves any of the categories CR, VGPR, PR, MR or SD as their maximum response. Median time to maximum response will be presented. |
| Secondary | Progression free survival | from registration to first documented evidence of disease progression or death (up to 100 weeks) | A progression-free survival curve will be calculated using the Kaplan Meier method and median PFS estimates will be presented. |
| Secondary | Compliance to therapy | from initial treatment received as per protocol until treatment withdrawal (up to 100 weeks) | Compliance to therapy will be summarised descriptively, including number of doses missed and number of dose reductions throughout the treatment period. |
| Secondary | Feasibility of panobinostat maintenance | up to 12 months | The duration of maintenance and reasons for stopping will be summarised |
| Secondary | Overall survival | from registration to date of death | Overall survival (OS) curves will be calculated using the Kaplan Meier method. Median OS, and OS estimates at 12 months, will be presented, if appropriate. |
| Secondary | The proportion of participants mobilising sufficient stem cells for transplant(out of those undergoing mobilisation) | up to 16 cycles of therapy (an expected average of 48 weeks) | To be determined by the satisfactory collection of sufficient numbers of stem cells to support high-dose chemotherapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27843120 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02145715
GET https://conductscience.org/api/trials/v1/NCT02145715/registered